- Home
- FEAM vs BLRX Comparison
FEAM vs BLRX Comparison
Compare FEAM & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FEAM
- BLRX
- Stock Information
- Founded
- FEAM 2016
- BLRX 2003
- Country
- FEAM United States
- BLRX Israel
- Employees
- FEAM N/A
- BLRX N/A
- Industry
- FEAM Major Chemicals
- BLRX Biotechnology: Pharmaceutical Preparations
- Sector
- FEAM Industrials
- BLRX Health Care
- Exchange
- FEAM Nasdaq
- BLRX Nasdaq
- Market Cap
- FEAM 46.9M
- BLRX 54.1M
- IPO Year
- FEAM N/A
- BLRX 2011
- Fundamental
- Price
- FEAM $0.71
- BLRX $0.51
- Analyst Decision
- FEAM Buy
- BLRX Strong Buy
- Analyst Count
- FEAM 4
- BLRX 2
- Target Price
- FEAM $4.19
- BLRX $11.50
- AVG Volume (30 Days)
- FEAM 153.6K
- BLRX 168.2K
- Earning Date
- FEAM 11-07-2024
- BLRX 11-18-2024
- Dividend Yield
- FEAM N/A
- BLRX N/A
- EPS Growth
- FEAM N/A
- BLRX N/A
- EPS
- FEAM N/A
- BLRX N/A
- Revenue
- FEAM N/A
- BLRX $17,048,000.00
- Revenue This Year
- FEAM N/A
- BLRX N/A
- Revenue Next Year
- FEAM $1,117.19
- BLRX N/A
- P/E Ratio
- FEAM N/A
- BLRX N/A
- Revenue Growth
- FEAM N/A
- BLRX N/A
- 52 Week Low
- FEAM $0.40
- BLRX $0.50
- 52 Week High
- FEAM $3.35
- BLRX $1.93
- Technical
- Relative Strength Index (RSI)
- FEAM 61.36
- BLRX 27.79
- Support Level
- FEAM $0.45
- BLRX $0.50
- Resistance Level
- FEAM $0.50
- BLRX $0.67
- Average True Range (ATR)
- FEAM 0.08
- BLRX 0.04
- MACD
- FEAM 0.04
- BLRX -0.01
- Stochastic Oscillator
- FEAM 78.11
- BLRX 2.94
About FEAM 5E Advanced Materials Inc.
5E Advanced Materials Inc is engaged boron specialty advanced materials and lithium with a focus on enabling decarbonization, including electric transportation, clean energy, and food security.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.